G3139, a Bcl-2 antisense oligodeoxynucleotide, induces clinical responses in VAD refractory myeloma

Leukemia

Volumn 18, Issue 6, 2004, Pages 1078-1084

  van de Donk, N W C J ^a   de Weerdt, O ^b   Veth, G ^b   Eurelings, M ^a   van Stralen, E ^a   Frankel, S R ^c   Hagenbeek, A ^a   Bloem, A C ^a   Lokhorst, H M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ST ANTONIUS HOSPITAL   (Netherlands)

^c Genta Incorporated   (United States)

Author keywords

Antisense oligodeoxynucleotide; Bcl 2; Chemosensitization; Drug resistance; Multiple myeloma

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CD14 ANTIGEN; CD16 ANTIGEN; CD19 ANTIGEN; CD3 ANTIGEN; CD38 ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; CD5 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; MESSENGER RNA; OBLIMERSEN; PREDNISONE; PROTEIN BCL 2; SYNDECAN 1; THALIDOMIDE; VINCRISTINE; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; VAD PROTOCOL;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; ARTICLE; B LYMPHOCYTE; CANCER GROWTH; CANCER SURVIVAL; CATHETER INFECTION; CHEMOSENSITIVITY; CLINICAL ARTICLE; CODON; CONTINUOUS INFUSION; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG TOLERABILITY; FATIGUE; FEASIBILITY STUDY; FEMALE; HUMAN; IN VITRO STUDY; INFECTION; INJECTION SITE; KIDNEY DISEASE; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MONOCYTE; MULTIPLE MYELOMA; MYELOMA CELL; NEUTROPENIA; OPEN READING FRAME; PERIPHERAL CIRCULATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS; SIDE EFFECT; T LYMPHOCYTE; THROMBOCYTOPENIA; THROMBOSIS; CLINICAL TRIAL; DRUG RESISTANCE; GENE THERAPY; GENETICS; MIDDLE AGED; PATHOLOGY; PHASE 2 CLINICAL TRIAL; THROMBOCYTE;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; B-LYMPHOCYTES; BLOOD PLATELETS; DEXAMETHASONE; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE THERAPY; HUMANS; MALE; MIDDLE AGED; MONOCYTES; MULTIPLE MYELOMA; OLIGONUCLEOTIDES, ANTISENSE; PROTO-ONCOGENE PROTEINS C-BCL-2; T-LYMPHOCYTES; VINCRISTINE;

EID: 2942666279     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403363     Document Type: Article

References (50)

1. Moalli PA, Pillay S, Weiner D, Leikin R, Rosen ST. A mechanism of resistance to glucocorticoids in multiple myeloma: transient expression of a truncated glucocorticoid receptor mRNA. Blood 1992; 79: 213-222.
2. Ishikawa H, Kawano MM, Okada K, Tanaka H, Tanabe O, Sakai A et al. Expressions of DNA topoisomerase I and II gene and the genes possibly related to drug resistance in human myeloma cells. Br J Haematol 1993; 83: 68-74.
3. Krett NL, Pillay S, Moalli PA, Greipp PR, Rosen ST. A variant glucocorticoid receptor messenger RNA is expressed in multiple myeloma patients. Cancer Res 1995; 55: 2727-2729.
4. Valkov NI, Sullivan DM. Drug resistance to DNA topoisomerase I and II inhibitors in human leukemia, lymphoma, and multiple myeloma. Semin Hematol 1997; 34 (4 Suppl 5): 48-62.
5. Linsenmeyer ME, Jefferson S, Wolf M, Matthews JP, Board PG, Woodcock DM. Levels of expression of the mdr1 gene and glutathione S-transferase genes 2 and 3 and response to chemotherapy in multiple myeloma. Br J Cancer 1992; 65: 471-475.
6. Dalton WS, Grogan TM, Meltzer PS, Scheper RJ, Durie BG, Taylor CW et al. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 1989; 7: 415-424.
7. Epstein J, Xiao HQ, Oba BK. P-glycoprotein expression in plasma-cell myeloma is associated with resistance to VAD. Blood 1989; 74: 913-917.
8. Sonneveld P, Durie BG, Lokhorst HM, Marie JP, Solbu G, Suciu S et al. Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON. Lancet 1992; 340: 255-259.
9. Grogan TM, Spier CM, Salmon SE, Matzner M, Rybski J, Weinstein RS et al. P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood 1993; 81: 490-495.
10. Raaijmakers HG, Izquierdo MA, Lokhorst HM, de Leeuw C, Belien JA, Bloem AC et al. Lung-resistance-related protein expression is a negative predictive factor for response to conventional low but not to intensified dose alkylating chemotherapy in multiple myeloma. Blood 1998; 91: 1029-1036.
11. Filipits M, Drach J, Pohl G, Schuster J, Stranzl T, Ackermann J et al. Expression of the lung resistance protein predicts poor outcome in patients with multiple myeloma. Clin Cancer Res 1999; 5: 2426-2430.
12. Spanswick VJ, Craddock C, Sekhar M, Mahendra P, Shankaranarayana P, Hughes RG et al. Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma. Blood 2002; 100: 224-229.
13. Solary E, Droin N, Bettaieb A, Corcos L, Dimanche-Boitrel MT, Garrido C. Positive and negative regulation of apoptotic pathways by cytotoxic agents in hematological malignancies. Leukemia 2000; 14: 1833-1849.
14. O'Gorman DM, Cotter TG. Molecular signals in anti-apoptotic survival pathways. Leukemia 2001; 15: 21-34.
15. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002; 108: 153-164.
16. Hamilton MS, Barker HF, Ball J, Drew M, Abbot SD, Franklin IM. Normal and neoplastic human plasma cells express bcl-2 antigen. Leukemia 1991; 5: 768-771.
17. Pettersson M, Jernberg-Wiklund H, Larsson LG, Sundstrom C, Givol I, Tsujimoto Y et al. Expression of the bcl-2 gene in human multiple myeloma cell lines and normal plasma cells. Blood 1992; 79: 495-502.
18. Sangfelt O, Osterborg A, Grander D, Anderbring E, Ost A, Mellstedt H et al. Response to interferon therapy in patients with multiple myeloma correlates with expression of the Bcl-2 oncoprotein. Int J Cancer 1995; 63: 190-192.
19. Ong F, van Nieuwkoop JA, Groot-Swings GM, Hermans J, Harvey MS, Kluin PM et al. Bcl-2 protein expression is not related to short survival in multiple myeloma. Leukemia 1995; 9: 1282-1284.
20. Harada N, Hata H, Yoshida M, Soniki T, Nagasaki A, Kuribayashi N et al. Expression of Bcl-2 family of proteins in fresh myeloma cells. Leukemia 1998; 12: 1817-1820.
21. Puthier D, Pellat-Deceunynck C, Barille S, Robillard N, Rapp MJ, Juge-Morineau N et al. Differential expression of Bcl-2 in human plasma cell disorders according to proliferation status and malignancy. Leukemia 1999; 13: 289-294.
22. Renner S, Weisz J, Krajewski S, Krajewska M, Reed JC, Lichtenstein A. Expression of BAX in plasma cell dyscrasias. Clin Cancer Res 2000; 6: 2371-2380.
23. Gross A, McDonnell JM, Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis. Genes Dev 1999; 13: 1899-1911.
24. Kroemer G, Reed JC. Mitochondrial control of cell death. Nat Med 2000; 6: 513-519.
25. Adrain C, Creagh EM, Martin SJ. Apoptosis-associated release of Smac/DIABLO from mitochondria requires active caspases and is blocked by Bcl-2. EMBO J 2001; 20: 6627-6636.
26. Debatin KM, Poncet D, Kroemer G. Chemotherapy: targeting the mitochondrial cell death pathway. Oncogene 2002; 21: 8786-8803.
27. McDonnell TJ, Korsmeyer SJ. Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14; 18). Nature 1991; 349: 254-256.
28. Strasser A, Harris AW, Cory S. E mu-bcl-2 transgene facilitates spontaneous transformation of early pre-B and immunoglobulin-secreting cells but not T cells. Oncogene 1993; 8: 1-9.
29. Tu Y, Xu FH, Liu J, Vescio R, Berenson J, Fady C, Lichtenstein A. Upregulated expression of BCL-2 in multiple myeloma cells induced by exposure to doxorubicin, etoposide, and hydrogen peroxide. Blood 1996; 88: 1805-1812.
30. Gazitt Y, Fey V, Thomas C, Alvarez R. Bcl-2 overexpression is associated with resistance to dexamethasone, but not melphalan, in multiple myeloma cells. Int J Oncol 1998; 13: 397-405.
31. Derenne S, Monia B, Dean NM, Taylor JK, Rapp MJ, Harousseau JL et al. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood 2002; 100: 194-199.
32. van de Donk NW, Kamphuis MM, Van Dijk M, Borst HP, Bloem AC, Lokhorst HM. Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein. Leukemia 2003; 17: 211-219.
33. Liu Q, Gazitt Y. Potentiation of dexamethasone-, paclitaxel-, and Ad-p53-induced apoptosis by Bcl-2 antisense oligodeoxynucleotides in drug-resistant multiple myeloma cells. Blood 2003; 101: 4105-4114.
34. Webb A, Cunningham D, Cotter F, Clarke PA, di Stefano F, Ross P et al. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 1997; 349: 1137-1141.
35. Waters JS, Webb A, Cunningham D, Clarke PA, Raynaud F, di Stefano F et al. Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 2000; 18: 1812-1823.
36. Rai KR, O'Brien S, Cunningham C, Turkina AG, Ochoa L, Frankel SR. Genasense (Bcl-2 Antisense) monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia: Phase 1 and 2 results. Blood 2002; 100: 384a.
37. Jansen B, Wacheck V, Heere-Ress E, Schlagbauer-Wadl H, Hoeller C, Lucas T et al. Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet 2000; 356: 1728-1733.
38. Rudin CM, Otterson GA, Mauer AM, Villalona-Calero MA, Tomek R, Prange B et al. A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer. Ann Oncol 2002; 13: 539-545.
39. Chi KN, Gleave ME, Klasa R, Murray N, Bryce C, Lopes de Menezes DE et al. A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. Clin Cancer Res 2001; 7: 3920-3927.
40. Ochoa L, Kuhn J, Salinas R, Hammond L, Hao D, Denis L. A phase 1, pharmacokinetic, and biologic correlative study of G3139 and irinotecan (CPT-11) in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2001; 20: 75a.
41. Marcucci G, Byrd JC, Dai G, Klisovic MI, Kourlas PJ, Young DC et al. Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood 2003; 101: 425-432.
42. Klasa RJ, Gillum AM, Klem RE, Frankel SR. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev 2002; 12: 193-213.
43. Segeren CM, Sonneveld P, van der HB, Baars JW, Biesma DH, Cornellissen JJ et al. Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma. Br J Haematol 1999; 105: 127-130.
44. Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 1115-1123.
45. Boersma-Vreugdenhil GR, Peeters T, Bast BJ. Translocation of the IgH locus is nearly ubiquitous in multiple myeloma as detected by immuno-FISH. Blood 2003; 101: 1653.
46. Blade J, Esteve J. Treatment approaches for relapsing and refractory multiple myeloma. Acta Oncol 2000; 39: 843-847.
47. Richardson PG, Schlossman RL, Weller E, Hideshima T, Mitsiades C, Davies F et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002; 100: 3063-3067.
48. Bishop MR, Iversen PL, Bayever E, Sharp JG, Greiner TC, Copple BL et al. Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies. J Clin Oncol 1996; 14: 1320-1326.
49. Glover JM, Leeds JM, Mant TG, Amin D, Kisner DL, Zuckerman JE et al. Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302). J Pharmacol Exp Ther 1997; 282: 1173-1180.
50. Veis DJ, Sorenson CM, Shutter JR, Korsmeyer SJ. Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. Cell 1993; 75: 229-240.